- Home
- COF vs VRTX Comparison
COF vs VRTX Comparison
Compare COF & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COF | VRTX |
|---|---|---|
| Founded | 1988 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8B | 115.7B |
| IPO Year | 1994 | 1991 |
Fundamental Metrics
Financial Performance| Metric | COF | VRTX |
|---|---|---|
| Price | $238.04 | $441.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 27 |
| Target Price | $264.06 | ★ $501.42 |
| AVG Volume (30 Days) | ★ 4.4M | 1.4M |
| Earning Date | 01-22-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.38 | ★ 14.22 |
| Revenue | ★ $28,886,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $96.71 | $11.01 |
| Revenue Next Year | $18.55 | $8.74 |
| P/E Ratio | $99.41 | ★ $31.03 |
| Revenue Growth | 9.02 | ★ 10.33 |
| 52 Week Low | $143.22 | $362.50 |
| 52 Week High | $259.64 | $519.68 |
Technical Indicators
Market Signals| Indicator | COF | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 43.64 |
| Support Level | $224.26 | $436.69 |
| Resistance Level | $259.64 | $487.52 |
| Average True Range (ATR) | 5.87 | 10.78 |
| MACD | -2.58 | -3.45 |
| Stochastic Oscillator | 38.57 | 10.39 |
Price Performance
Historical ComparisonAbout COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.